Scinai Immunotherapeutics Ltd. Financials
Scinai Immunotherapeutics Ltd. (SCNI) reported $1.3M in revenue for fiscal year 2025, up 99.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Equity-funded development work is sustaining the company while small revenue gains still arrive with negative gross profit.
Between FY2024 and FY2025, revenue nearly doubled to$1.3M but gross loss deepened to-$2.7M , so added sales did not yet improve unit economics. At the same time, operating cash flow was-$6.0M while capex was only$24K , showing the cash drain comes from ongoing operations, not from building a capital-heavy asset base.
The narrower operating loss in FY2025 came mainly from lower R&D spending, not from scale: research expense fell to
The balance sheet is not debt-heavy but externally financed: cash ended FY2025 at
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Scinai Immunotherapeutics Ltd.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Scinai Immunotherapeutics Ltd.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 4/100.
Not available for Scinai Immunotherapeutics Ltd., and counted as zero in the overall score.
Scinai Immunotherapeutics Ltd. has a moderate D/E ratio of 0.43. This balance of debt and equity financing earns a leverage score of 62/100.
Scinai Immunotherapeutics Ltd.'s current ratio of 1.30 indicates adequate short-term liquidity, earning a score of 33/100. The company can meet its near-term obligations, though with limited headroom.
Scinai Immunotherapeutics Ltd.'s reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 3/100.
Scinai Immunotherapeutics Ltd. posts a -102.5% return on equity (ROE), meaning it loses $103 for every $100 of shareholders' equity. This results in a returns score of 6/100. This is down from 48.1% the prior year.
Scinai Immunotherapeutics Ltd. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Scinai Immunotherapeutics Ltd. reported a net loss of $8.3M while operations used $6.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Scinai Immunotherapeutics Ltd. generated $1.3M in revenue in fiscal year 2025. This represents an increase of 99.2% from the prior year.
Scinai Immunotherapeutics Ltd.'s EBITDA was -$6.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.4% from the prior year.
Scinai Immunotherapeutics Ltd. reported -$8.3M in net income in fiscal year 2025. This represents a decrease of 273.2% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Scinai Immunotherapeutics Ltd. recorded an outflow of $6.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 4.6% from the prior year.
Scinai Immunotherapeutics Ltd. held $1.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Scinai Immunotherapeutics Ltd.'s ROE was -102.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 150.6 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Scinai Immunotherapeutics Ltd. invested $2.4M in research and development in fiscal year 2025. This represents a decrease of 57.2% from the prior year.
Scinai Immunotherapeutics Ltd. invested $24K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 100.0% from the prior year.
Not reported for fiscal year 2025.
SCNI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Revenue | $1.3M+99.2% | $658K | N/A | N/A | N/A |
| Cost of Revenue | $4.0M+220.1% | $1.2M | N/A | N/A | N/A |
| Gross Profit | -$2.7M-357.2% | -$580K | N/A | N/A | N/A |
| R&D Expenses | $2.4M-57.2% | $5.5M+6.2% | $5.2M-9.6% | $5.8M+77.4% | $3.2M |
| SG&A Expenses | $2.5M-0.2% | $2.5M-43.9% | $4.5M-14.9% | $5.3M-30.5% | $7.6M |
| Operating Income | -$7.5M+12.7% | -$8.6M+11.0% | -$9.7M+12.3% | -$11.1M-1.8% | -$10.9M |
| Interest Expense | N/A | N/A | $343K-2.3% | $351K+4.5% | $336K |
| Net Income | -$8.3M-273.2% | $4.8M+173.8% | -$6.5M-12.1% | -$5.8M+29.4% | -$8.2M |
| EPS (Diluted) | N/A | N/A | $0.00 | $0.01+150.0% | -$0.02 |
Not reported in any period shown, so not listed: Income Tax.
SCNI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Total Assets | $11.6M-13.5% | $13.4M-23.0% | $17.5M-35.4% | $27.1M-15.5% | $32.0M |
| Current Assets | $2.1M-14.1% | $2.4M-56.1% | $5.4M-62.1% | $14.4M-19.5% | $17.8M |
| Cash & Equivalents | $1.7M-15.4% | $2.0M-59.7% | $4.9M-65.4% | $14.1M-19.0% | $17.4M |
| Accounts Receivable | $73K-12.0% | $83K | N/A | N/A | N/A |
| Total Liabilities | $3.5M+1.5% | $3.5M-84.3% | $22.0M-23.5% | $28.8M-7.2% | $31.1M |
| Current Liabilities | $1.6M-12.2% | $1.8M+1.5% | $1.8M-23.9% | $2.3M-4.3% | $2.4M |
| Total Equity | $8.1M-18.8% | $10.0M+318.4% | -$4.6M-159.6% | -$1.8M-279.2% | $982K |
| Retained Earnings | -$125.8M-7.1% | -$117.5M+3.9% | -$122.3M-5.6% | -$115.8M-5.3% | -$110.0M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
SCNI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$6.0M+4.8% | -$6.3M+32.5% | -$9.4M-29.1% | -$7.3M+2.2% | -$7.4M |
| Capital Expenditures | $24K+100.0% | $12K-98.1% | $637K-23.8% | $836K+501.4% | $139K |
| Free Cash Flow | -$6.1M+4.6% | -$6.3M+36.7% | -$10.0M-23.7% | -$8.1M-7.1% | -$7.6M |
| Investing Cash Flow | -$24K-100.0% | -$12K+98.1% | -$637K+23.8% | -$836K-501.4% | -$139K |
| Financing Cash Flow | $5.8M+67.7% | $3.4M+216.9% | $1.1M-84.0% | $6.8M-68.4% | $21.4M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
SCNI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Gross Margin | -202.3% | -88.1% | N/A | N/A | N/A |
| Operating Margin | -575.3% | -1312.8% | N/A | N/A | N/A |
| Net Margin | -633.6% | 728.9% | N/A | N/A | N/A |
| Return on Equity | -102.5%-150.6pp | 48.1% | N/A | N/A | -835.6% |
| Return on Assets | -71.5%-107.1pp | 35.7%+72.9pp | -37.2%-15.8pp | -21.4%+4.2pp | -25.6% |
| Current Ratio | 1.300.0x | 1.32-1.7x | 3.06-3.1x | 6.15-1.2x | 7.30 |
| Debt-to-Equity | 0.43+0.1x | 0.35 | N/A | N/A | 31.62 |
| FCF Margin | -461.9% | -964.6% | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Scinai Immunotherapeutics Ltd. Ranks
Frequently Asked Questions
What is Scinai Immunotherapeutics Ltd.'s annual revenue?
Scinai Immunotherapeutics Ltd. (SCNI) reported $1.3M in total revenue for fiscal year 2025. This represents a 99.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Scinai Immunotherapeutics Ltd.'s revenue growing?
Scinai Immunotherapeutics Ltd. (SCNI) revenue grew by 99.2% year-over-year, from $658K to $1.3M in fiscal year 2025.
Is Scinai Immunotherapeutics Ltd. profitable?
No, Scinai Immunotherapeutics Ltd. (SCNI) reported a net income of -$8.3M in fiscal year 2025.
What is Scinai Immunotherapeutics Ltd.'s EBITDA?
Scinai Immunotherapeutics Ltd. (SCNI) had EBITDA of -$6.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Scinai Immunotherapeutics Ltd.'s return on equity (ROE)?
Scinai Immunotherapeutics Ltd. (SCNI) has a return on equity of -102.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Scinai Immunotherapeutics Ltd.'s free cash flow?
Scinai Immunotherapeutics Ltd. (SCNI) recorded an outflow of $6.1M in free cash flow during fiscal year 2025. This represents a 4.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Scinai Immunotherapeutics Ltd.'s operating cash flow?
Scinai Immunotherapeutics Ltd. (SCNI) recorded an outflow of $6.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Scinai Immunotherapeutics Ltd.'s total assets?
Scinai Immunotherapeutics Ltd. (SCNI) had $11.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Scinai Immunotherapeutics Ltd.'s capital expenditures?
Scinai Immunotherapeutics Ltd. (SCNI) invested $24K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Scinai Immunotherapeutics Ltd. spend on research and development?
Scinai Immunotherapeutics Ltd. (SCNI) invested $2.4M in research and development during fiscal year 2025.
What is Scinai Immunotherapeutics Ltd.'s current ratio?
Scinai Immunotherapeutics Ltd. (SCNI) had a current ratio of 1.30 as of fiscal year 2025, which is considered adequate.
What is Scinai Immunotherapeutics Ltd.'s debt-to-equity ratio?
Scinai Immunotherapeutics Ltd. (SCNI) had a debt-to-equity ratio of 0.43 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Scinai Immunotherapeutics Ltd.'s return on assets (ROA)?
Scinai Immunotherapeutics Ltd. (SCNI) had a return on assets of -71.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Scinai Immunotherapeutics Ltd.'s cash runway?
Based on fiscal year 2025 data, Scinai Immunotherapeutics Ltd. (SCNI) had $1.7M in cash against an annual operating cash burn of $6.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Scinai Immunotherapeutics Ltd.'s Piotroski F-Score?
Scinai Immunotherapeutics Ltd. (SCNI) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Scinai Immunotherapeutics Ltd.'s earnings high quality?
Scinai Immunotherapeutics Ltd. (SCNI) reported a net loss of $8.3M while operations used $6.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Scinai Immunotherapeutics Ltd.?
Scinai Immunotherapeutics Ltd. (SCNI) scores 18 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.